PATENT CLAIM ANALYSIS

Application Number: 15937594
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-10
Patent Classification: ["514", "223200"]

Abstract:
Provided are immediate or prolonged administration of certain potassium ATP (K ATP ) channel openers to a subject to achieve novel pharmacodynamic, pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving K ATP  channels. Also provided are pharmaceutical formulations, methods of administration and dosing of K ATP  channel openers that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering K ATP  channel openers with other drugs to treat diseases of humans and animals.

Claim (Index 23):
The method of  claim 21 , wherein the depression treating drug is selected from the group consisting of citalopram hydrobromide, escitalopram hydrobromide, fluvoxamine maleate, paroxetine hydrochloride, fluoxetine hydrochloride, setraline hydrochloride, amitriptyline hydrochloride, desipramine hydrochloride, nortriptyline hydrochloride, duloxetine hydrochloride, venlafaxine hydrochloride, phenelzine sulfate, bupropion hydrochloride, and mirtazapine.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 90.0
- Lexical Diversity: 1.63333
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14458032', '12391990', '14940018', '15195826', '15671792']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8351708509691331
- 35 USC 102 Novelty (BERT): 0.5843120670896444
- Combined Prediction Score: 0.8100849725811843
- Mean Citation Score: 369.046582
- Max Citation Score: 374.8041
- Similarity Product: 239.8705527465105

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test